
    
      Treatment group A 0 - 6 months: Adalimumab 40 mg eow + methotrexate rapidly titrated to 20 mg
      weekly + prednisone 50 mg/d tapered to 6.25 mg 6 - 12 months: Adalimumab 40 mg eow plus
      methotrexate 20 mg weekly group B 0 - 6 months: Adalimumab 40 mg eow + methotrexate rapidly
      titrated to 20 mg weekly + placebo 6 - 12 months: Adalimumab 40 mg eow + methotrexate rapidly
      titrated to 20 mg weekly

      Follow up period - Open Label phase:

      Patients achieving clinical remission will be than treated only with MTX and observed for
      another 12 months period. Patients who do not achieve clinical remission or patients who will
      experience a relapse of the disease will be treated according to standard of care (SOC)
      modalities.
    
  